Sunday Prep 9/12 - $ABUS Higher The Better! The higher the better on this name, but will be stalking it for lower highs and an area to get short with defined risk.
−0.44USD
−72.85 MUSD
18.14 MUSD
136.99 M
About Arbutus Biopharma Corporation
Sector
CEO
Michael J. McElhaugh
Headquarters
Warminster
Website
Employees (FY)
73
Founded
2005
ISIN
CA03879J1003
FIGI
BBG000RR8V85
Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics that target specific viral diseases. It focuses on the Hepatitis B virus, SARS-CoV-2, and other coronaviruses. The company was founded on October 6, 2005 and is headquartered in Warminster, PA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of ABUS is 2.73 USD — it has decreased by 1.80% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Arbutus Biopharma Corporation stocks are traded under the ticker ABUS.
Arbutus Biopharma Corporation is going to release the next earnings report on May 2, 2024. Keep track of upcoming events with our Earnings Calendar.
ABUS stock is 4.09% volatile and has beta coefficient of 0.67. Check out the list of the most volatile stocks — is Arbutus Biopharma Corporation there?
One year price forecast for Arbutus Biopharma Corporation has a max estimate of 5.00 USD and a min estimate of 4.00 USD.
ABUS earnings for the last quarter are −0.12 USD whereas the estimation was −0.11 USD which accounts for −7.14% surprise. Estimated earnings for the next quarter are −0.12 USD. See more details about Arbutus Biopharma Corporation earnings.
Arbutus Biopharma Corporation revenue for the last quarter amounts to 4.66 M USD despite the estimated figure of 4.75 M USD. In the next quarter revenue is expected to reach 4.78 M USD.
Yes, you can track Arbutus Biopharma Corporation financials in yearly and quarterly reports right on TradingView.
ABUS stock has fallen by 7.46% compared to the previous week, the month change is a 8.33% rise, over the last year Arbutus Biopharma Corporation has showed a 7.14% decrease.
ABUS net income for the last quarter is −19.31 M USD, while the quarter before that showed −20.10 M USD of net income which accounts for 3.94% change. Track more Arbutus Biopharma Corporation financial stats to get the full picture.
Today Arbutus Biopharma Corporation has the market capitalization of 500.89 M, it has increased by 22.62% over the last week.
No, ABUS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, ABUS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Arbutus Biopharma Corporation stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 19, 2024, the company has 73.00 employees. See our rating of the largest employees — is Arbutus Biopharma Corporation on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Arbutus Biopharma Corporation technincal analysis shows the sell today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Arbutus Biopharma Corporation stock shows the neutral signal. See more of Arbutus Biopharma Corporation technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Arbutus Biopharma Corporation future price: according to them, ABUS price has a max estimate of 5.00 USD and a min estimate of 4.00 USD. Read a more detailed Arbutus Biopharma Corporation forecast: see what analysts think of Arbutus Biopharma Corporation and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Arbutus Biopharma Corporation EBITDA is −76.63 M USD, and current EBITDA margin is −422.41%. See more stats in Arbutus Biopharma Corporation financial statements.